OmniSeq News

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Launch of Immune Report Card

BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...

read more

Follow Us on Twitter

#JITC Research: Predicting response to checkpoint #inhibitors in #melanoma beyond PD-L1 and mutational burden https://t.co/NtD7muR0F1

Thanks to all of our collaborators (9 Institutions @RoswellPark, @FoxChaseCancer, @columbiacancer, @WeillCornell and others) that contributed to the Melanoma Immune Landscape paper pushing our understanding of prediction to response to immune therapy.

https://t.co/XDSA8jDWf4

Carl Morrison compares the benefits and challenges of immunohistochemistry (IHC) and RNA sequencing (RNA-seq) for #immunotherapy

A focused, simple and cost-effective, NY State DoH CLIA approved assay - Enjoy "Searching for OmniSeq MSI NGS" #AACR18 #cancer #Immunotherapy

In light of the discussion @AACR , OmniSeq CEO Mark Gardner discusses why mutational burden is a necessary, but not sufficient indicator for #Cancer #immunotherapy response prediction #AACR18

Load More...